Table 2.
Univariate analyses of the prognostic factors for survival
| Factor | No. | MST (months) | 2-year OS(%) | 95%CI | P value |
|---|---|---|---|---|---|
| Age | |||||
| < 70 | 18 | 16 | 33.3 | 11.5–55.1 | 0.070 |
| ≥70 | 29 | 17 | 20.7 | 6.0–35.4 | |
| Sex | |||||
| Male | 35 | 16 | 20.0 | 6.7–33.3 | 0.083 |
| Female | 12 | 17 | 41.7 | 13.9–69.5 | |
| ECOG-PS | |||||
| 0–1 | 24 | 18 | 37.5 | 18.1–56.9 | 0.014 |
| 2–3 | 23 | 15 | 13.0 | 0.26–25.74 | |
| Initial site | |||||
| Cervical +upper thoracic | 20 | 17 | 30.0 | 10.0–50.0 | 0.100 |
| Middle thoracic | 18 | 16 | 33.3 | 11.5–55.1 | |
| Lower thoracic | 9 | 12 | 0 | – | |
| Recurrence pattern | |||||
| Local | 37 | 17 | 32.4 | 17.3–47.5 | 0.048 |
| Local +nodal | 10 | 14 | 0 | – | |
| Time to recurrence | |||||
| < 24 months | 19 | 12 | 15.8 | 0.5–31.1 | 0.006 |
| ≥24 months | 28 | 18 | 32.1 | 14.9–49.3 | |
| Chemotherapy | |||||
| Yes | 13 | 18 | 23.1 | 0.2–46.0 | 0.812 |
| No | 34 | 16 | 26.5 | 11.6–41.4 | |
| Re-RT dose | |||||
| <50Gy | 15 | 11 | 0 | – | < 0.001 |
| ≥50Gy | 32 | 18 | 37.5 | 20.6–54.4 | |
ECOG-PS Eastern Cooperative Oncology Group Performance Status, Re-RT re-irradiation, MST median survival time, OS overall survival, CI confidence interval